Pharma & Drug Safety

Alpha-Polyglutamic Acid-Zinc Compositions for Cancer Treatment

The European Patent Office published patent application EP3703708A1 for alpha-polyglutamic acid-zinc compositions for treating cancer, filed by Xylonix Pte. Ltd. The invention covers pharmaceutical compositions using alpha-polyglutamic acid chelated with zinc for anticancer applications, classified under IPC A61K 33/30, A61K 47/64, and A61P 35/00. The patent designates all EU member states and other European countries.

Adenosine Derivatives for Liver Disease Treatment

The European Patent Office granted patent EP3533452A1 to Future Medicine Co., Ltd. covering adenosine derivatives for preventing and treating nonalcoholic steatohepatitis, hepatic fibrosis, and liver cirrhosis. The patent was published April 1, 2026, with Kind A1 designation indicating inclusion of the European search report. The patent designates 44 European states including EU member states, the United Kingdom, Switzerland, Norway, Iceland, and Turkey.

Methods of Treating Eosinophilic Esophagitis

European Patent Office granted patent EP3500264A1 to Adare Pharmaceuticals US, L.P. covering methods of treating eosinophilic esophagitis using pharmaceutical compositions. The patent names Brian Meltzer and Gail Comer as inventors and specifies A61K classifications for the treatment formulations and methods.

Use of Gaboxadol for Treatment of Tourette Syndrome, Tics and Stuttering

The European Patent Office published patent application EP3833351A1 for Ovid Therapeutics Inc., covering the use of gaboxadol for treating Tourette syndrome, tics, and stuttering. The patent is designated across 31 European states including Germany, France, the United Kingdom, Italy, Spain, the Netherlands, and other EU/EEA countries. IPC classifications include A61K 31/473, covering pharmaceutical compositions for neurological treatments.

EP3266457A1 - Bile Acid Recycling Inhibitors for Pediatric Cholestatic Liver Diseases

The European Patent Office granted Patent EP3266457A1 to Shire Human Genetic Therapies, Inc. covering bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases. The patent application includes claims related to pharmaceutical compositions and methods of treatment. The designation covers 37 European states including Austria, Belgium, Switzerland, Germany, France, and the United Kingdom.

In Vitro Bioproduction of Polyhydroxyalkanoate Monomers

USPTO published patent application US20260098283A1 by inventor Stephen Quirk for an enzymatic process to produce homogeneous chain length polyhydroxyalkanoate (PHA) monomers and polymers with chain lengths of at least eight carbons from long-chain fatty acids. The process enables specific, controlled production of PHA materials through in vitro enzyme contact with long-chain fatty acid precursors.

CO2 Conversion to C2+ Chemicals via Electrochemical and Microbial Process

USPTO published patent application US20260098282A1 disclosing a method for converting carbon dioxide to higher value C2+ chemicals using an electrochemical cell with a carbon dioxide reducing catalyst combined with microbial conversion. The application was filed on September 23, 2023, by inventors Peng Zhang, Kainan Chen, Joshua Shuhua Yuan, and Susie Y. Dai. The publication makes the application publicly available but does not constitute a granted patent.

BEST1 Vectors for Retinal Dystrophy Treatment

The USPTO published patent application US20260098277A1 covering BEST1-targeted expression constructs, nucleic acid vectors, and pharmaceutical compositions for treating BEST1-associated retinal dystrophies including autosomal dominant bestrophinopathies. The application includes BEST1-targeted shRNAs, BEST1 coding sequences, promoters, and regulatory elements designed to improve functional BEST1 expression in subjects with BEST1 mutations. This published application represents an early-stage intellectual property filing with no granted rights or compliance obligations established.

Methods of Improving Unique Molecular Index Ligation Efficiency

Illumina, Inc. has filed a patent application (US20260098256A1) for methods and adapter pools that improve unique molecular index (UMI) ligation efficiency in nucleic acid sequencing applications. The invention enables more accurate quantification of polynucleotide fragments by providing UMIs that are uniquely associable with individual fragments. The application was published April 9, 2026, with a filing date of December 12, 2025. Biotechnology companies developing next-generation sequencing technologies may need to review this application to assess potential impacts on their IP strategies or freedom-to-operate analysis. Researchers and diagnostic developers using UMI-based sequencing methods should monitor this and related patent activity for potential licensing implications.

Lysis Vessel with Dual Membranes and Non-Magnetic Beads for On-Board Cell Lysis

USPTO published patent application US20260098253A1 assigned to Gen-Probe Incorporated. The application covers a lysis vessel for performing cell lysis that includes a laterally extending member and sleeve with dual porous membranes, non-magnetic beads, and at least one magnetic element contained within a lysis chamber. Filing date was December 11, 2025, under application number 19416385.